GI Diagnostics Growth ALPCO is expanding its gastrointestinal diagnostic portfolio with the FDA 510(k) cleared Calprotectin Immunoturbidimetric Assay and recent European launch, presenting a sales opportunity to labs seeking GI biomarkers and immunoassay solutions.

Global Partnerships Strategic collaborations with Dynex Technologies and earlier alliances with GeneProof and Gold Standard Diagnostics indicate a pattern of integrated automated and benchtop systems, suggesting cross-sell opportunities to labs already using partner ecosystems.

Clinical and Research Synergy As a provider for both research and clinical laboratories with infectious and gastroenterological focus, ALPCO serves dual markets, enabling targeted outreach to translational research facilities and hospital/clinical labs seeking reliable diagnostic tools.

Growing Leadership Recent CEO appointment and global launch activities point to a company in strategic growth mode, signaling readiness for channel expansion, distributor partnerships, and enterprise-level purchasing agreements.

Digital and Sales Enablement Existing tech stack includes Salesforce Marketing Cloud and analytics tools, suggesting potential for segmented digital campaigns, account-based selling, and data-driven lead nurturing to convert lab customers and procurement specialists.